Skip to main content

Table 1 Characteristics of included studies and quality evaluation of documents

From: Predictive value of neutrophil to lymphocyte ratio in patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention: a meta-analysis

Study Study Country male,% Age
mean(SD)
NLR
grouping
Follow-up
(days)
Observation index Quality
score
Akpek, [7] 2012 Prospective cohort study Turkey,
China,
USA
327(78.0) 59.4 ± =12.4 ≤3.3
> 3.3
6.7(mean) In-hospital: in-stent thrombosis, MACE, nonfatal MI,
no reflow, all-cause mortality
6
Arbel, [8] 2014 Prospective cohort study Israel 436(81.0) 61 ± 13 <  6.5
≥6.5
1044 (median) In-hospital: arrhythmia
Long-term: all-cause mortality
6
Han, [9]
2013
Prospective cohort study Korea 247(75.8) 61.9 ± 12.3 ≤3.30
3.31–6.52
> 6.53
360(total) In-hospital: MACE, nonfatal MI, no reflow, all-cause mortality
Long-term: nonfatal MI, MACE, all-cause mortality
5
He, [10]
2014
Prospective cohort study China 546(78.9) 60.27 < 3.16
3.16–4.75
> 4.75
3395 (median) In-hospital: arrhythmia, no reflow, cardiac mortality, all-cause mortality
Long-term: cardiac mortality, all-cause mortality, MACE
5
Her, [11]
2017
Prospective cohort study Korea 140(81.4) 57.1 ± 12.4 < 5.8
≥5.8
1230(median) In-hospital: MACE
12 months follow-up: MACE,
Long-term: all-cause mortality, nonfatal MI
6
Park JinJoo,
2013 [12]
Prospective cohort study Korea 235(72.0) 60.9 ± 13.9 < 5.44
≥5.44
1092(median) Long-term: all-cause mortality 6
Kaya, [13] 2013 Prospective cohort study Turkey,
China,
USA
535(78.4) 60.8 < 2.3
2.3–4.4
> 4.4
1299(median) In-hospital: in-stent thrombosis, MACE, non-fatal MI, no reflow,
cardiac mortality,
Long-term: Non-fatal MI,MACE, cardiac mortality
6
Pan, [14]
2015
Prospective cohort study China 496(78.0) 59.27 ± 11.27 <  3.0
3.0–6.40
>  6.40
360(total) In-hospital: angina, arrhythmia, cardiac mortality,
12 months follow-up: all-cause mortality
6
Sen, [15] 2013 Prospective cohort study Turkey 176(86.3) 55.8 <  3.30
3.30–4.56
> 4.56
1140 (total) In-hospital: all-cause mortality, MACE, no reflowAt three-year follow up, all-cause mortality, MACE 6
Shen, [16]
2010
Prospective cohort study China 329(59.7) 61 1.44–3.45
3.45–4.81
4.82–6.46
6.47–22.57
1898 (median) In-hospital: all-cause mortality
Long-term: all-cause mortality
6
Tanriverdi, [17] 2017 Prospective cohort study Turkey 285(77.4) 59.6 < 5.47
≥ 5.47
3.8(mean) In-hospital: all-cause mortality 6
Zuin, [18] 2017 Prospective cohort study Italy 1724(71.8) 64.5 < 2.1
3.4–4.1
> 4.1
363(median) Long-term: cardiovascular mortality 6
Ergelen, [19] 2014 Retrospective cohort study Turkey 2015(83.6) 56.4 ≤6.97
> 6.97
630 (median) In hospital: AHF, MACE, nonfatal MI, no reflow, cardiovascular mortality,
Long-term: MACE, nonfatal MI, cardiovascular mortality
5
Gazi, [20] 2015 Retrospective cohort study Turkey 417(79.9) 62.57 ≤5.77
> 5.77
5.7(mean) In-hospital: AHF, angina, arrhythmia, all-cause mortality, nonfatal MI 6